| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5442049 | NOVARTIS | Oligonucleotides for modulating the effects of cytomegalovirus infections |
Aug, 2012
(11 years ago) | |
| US5595978 | NOVARTIS | Composition and method for treatment of CMV retinites |
Aug, 2012
(11 years ago) | |
Vitravene Preservative Free is owned by Novartis.
Vitravene Preservative Free contains Fomivirsen Sodium.
Vitravene Preservative Free has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Vitravene Preservative Free are:
- US5442049
- US5595978
Vitravene Preservative Free was authorised for market use on 26 August, 1998.
Vitravene Preservative Free is available in injectable;injection dosage forms.
Vitravene Preservative Free can be used as treatment of cmv retinitis by intravitreal admin of a phosphorothioate oligonucleotide capable of hybridizing with cmv mrna.
The generics of Vitravene Preservative Free are possible to be released after 15 August, 2012.
Drugs and Companies using FOMIVIRSEN SODIUM ingredient
Market Authorisation Date: 26 August, 1998
Treatment: Treatment of cmv retinitis by intravitreal admin of a phosphorothioate oligonucleotide capable of hybridizing with cmv mrna
Dosage: INJECTABLE;INJECTION
VITRAVENE PRESERVATIVE FREE family patents
